Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
NCT ID: NCT07131956
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2025-12-31
2028-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer
NCT01376674
PD-L1-expressing Regulatory T Cells in Localized Prostate Cancer Patients Undergoing Iodine-125 Permanent Brachytherapy
NCT04369508
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
NCT01834001
Detection of Micrometastases in Lymph Nodes of Patients With Prostate Cancer
NCT01615965
Liquid Biopsy Under PSMA Radioligand Therapy
NCT07118436
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Primary brachytherapy
Patients receiving sole primary brachytherapy (either LDR-BT or HDR-BT) for low or low intermediate risk prostate cancer
No interventions assigned to this group
Salvage brachytherapy
Patients receiving sole brachytherapy (either PDR-BT or HDR-BT) for locally recurrent prostate cancer after prior irradiation with prostate in situ
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No previous treatment for prostate cancer
* Age ≥ 18 years
* HDR- or PDR-BT
* No radiation therapy within three months before salvage treatment
* Complete documentation available on previous treatment for prostate cancer
* No history of prostatectomy
* Age ≥ 18 years
Exclusion Criteria
* patients under bloodthinning medication
* substance abuse
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bavarian Cancer Research Center (BZKF)
UNKNOWN
University Hospital Augsburg
OTHER
Ludwig-Maximilians - University of Munich
OTHER
University of Erlangen-Nürnberg Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Claudia Schweizer
Claudia Schweizer MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claudia Schweizer, MD
Role: PRINCIPAL_INVESTIGATOR
Strahlenklinik Universitätsklinikum Erlangen
Anna-Jasmina Donaubauer, Dr. rer. nat.
Role: PRINCIPAL_INVESTIGATOR
Strahlenklinik Universitätsklinikum Erlangen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinik für Strahlentherapie
Augsburg, Bavaria, Germany
Strahlenklinik Erlangen
Erlangen, Bavaria, Germany
Klinik und Poliklinik für Strahlentherapie und Radioonkologie
Munich, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Anna-Jasmina Donaubauer, Dr. rer. nat.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Klinik und Poliklinik für Strahlentherapie und Radioonkologie
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ImmunBioProBrachy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.